Xenetic Biosciences, Inc. Share Price
NASDAQ: XBIO | Micro CapXenetic Biosciences, Inc. Stock Performance
Open $3.87 | Prev. Close $3.85 | Circuit Range N/A |
Day Range $3.87 - $3.92 | Year Range $1.92 - $13.87 | Volume 605 |
Average Traded $3.89 |
Xenetic Biosciences, Inc. Share Price Today
As of 29 August 2026, Xenetic Biosciences, Inc.'s share price is $3.91. The stock opened at $3.87, compared to its previous close of $3.85. During today's trading session, Xenetic Biosciences, Inc.'s share price traded between $3.87 and $3.92, with an average price of $3.89. Over the past 52 weeks, the stock has recorded a high of $13.87 and a low of $1.92. In terms of performance, Xenetic Biosciences, Inc.'s share price has risen by 62.92% over the last six months and is up 33.81% on a year-on-year basis.
Xenetic Biosciences, Inc. Share Price Chart
Xenetic Biosciences, Inc. Stock Fundamentals & Key Indicators
Market Cap $6.65M | PE Ratio (TTM) -2.47 | Dividend Yield N/A |
EPS (TTM) $-1.58 | Revenue (TTM) $2.98M | Return On Equity (TTM) -36.25% |
Profit Margin -90.07% | Debt to Equity 0.13 | Quarterly Earnings Growth YoY -16.78% |
Xenetic Biosciences, Inc. Quarterly Profit & Loss
All figures in USD
Xenetic Biosciences, Inc. Annual Profit & Loss
All figures in USD
About Xenetic Biosciences, Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Xenetic Biosciences, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.75 | $3.85 | +45.64% |
Jul 2026 | $2.85 | $2.64 | -12.29% |
Jun 2026 | $3.14 | $3.01 | -3.83% |
May 2026 | $3.15 | $3.13 | +1.29% |
Apr 2026 | $2.98 | $3.09 | +13.19% |
Mar 2026 | $2.52 | $2.73 | +13.75% |
Feb 2026 | $2.25 | $2.40 | +5.73% |
Jan 2026 | $2.15 | $2.27 | +6.57% |
Dec 2025 | $2.50 | $2.13 | -21.11% |
Nov 2025 | $3.17 | $2.70 | -18.80% |
Oct 2025 | $3.15 | $3.33 | +7.61% |
Sep 2025 | $2.91 | $3.09 | +5.75% |
XBIO Share Price FAQs
What is Xenetic Biosciences, Inc. share price today?
What is the 52 week high and 52 week low of Xenetic Biosciences, Inc. stock?
What is XBIO's market capitalisation today?
What is XBIO's net income for the last quarter?
What is the 5 year returns of XBIO?
What is the high & low stock price of XBIO today?
Can I buy XBIO shares in India?